1. Home
  2. KYMR vs CUZ Comparison

KYMR vs CUZ Comparison

Compare KYMR & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYMR
  • CUZ
  • Stock Information
  • Founded
  • KYMR 2015
  • CUZ 1958
  • Country
  • KYMR United States
  • CUZ United States
  • Employees
  • KYMR N/A
  • CUZ N/A
  • Industry
  • KYMR Medicinal Chemicals and Botanical Products
  • CUZ Real Estate Investment Trusts
  • Sector
  • KYMR Health Care
  • CUZ Real Estate
  • Exchange
  • KYMR Nasdaq
  • CUZ Nasdaq
  • Market Cap
  • KYMR 4.7B
  • CUZ 4.2B
  • IPO Year
  • KYMR 2020
  • CUZ N/A
  • Fundamental
  • Price
  • KYMR $67.94
  • CUZ $25.95
  • Analyst Decision
  • KYMR Strong Buy
  • CUZ Buy
  • Analyst Count
  • KYMR 19
  • CUZ 11
  • Target Price
  • KYMR $68.95
  • CUZ $31.73
  • AVG Volume (30 Days)
  • KYMR 696.1K
  • CUZ 1.5M
  • Earning Date
  • KYMR 11-04-2025
  • CUZ 10-30-2025
  • Dividend Yield
  • KYMR N/A
  • CUZ 5.01%
  • EPS Growth
  • KYMR N/A
  • CUZ 3.48
  • EPS
  • KYMR N/A
  • CUZ 0.35
  • Revenue
  • KYMR $43,735,000.00
  • CUZ $955,949,000.00
  • Revenue This Year
  • KYMR $60.88
  • CUZ $14.63
  • Revenue Next Year
  • KYMR N/A
  • CUZ $2.97
  • P/E Ratio
  • KYMR N/A
  • CUZ $73.68
  • Revenue Growth
  • KYMR N/A
  • CUZ 15.46
  • 52 Week Low
  • KYMR $19.45
  • CUZ $24.07
  • 52 Week High
  • KYMR $68.80
  • CUZ $32.55
  • Technical
  • Relative Strength Index (RSI)
  • KYMR 68.81
  • CUZ 50.20
  • Support Level
  • KYMR $63.86
  • CUZ $24.69
  • Resistance Level
  • KYMR $68.80
  • CUZ $25.47
  • Average True Range (ATR)
  • KYMR 3.52
  • CUZ 0.54
  • MACD
  • KYMR 0.19
  • CUZ 0.08
  • Stochastic Oscillator
  • KYMR 94.07
  • CUZ 74.40

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

Share on Social Networks: